Lanean...

Nivolumab in melanoma: latest evidence and clinical potential

Melanoma has historically been considered a refractory disease with few if any options in the advanced/metastatic setting. Advances in both immune and genetically targeted treatment approaches have revolutionized the spectrum of treatment options for melanoma patients over the last several years. Re...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Johnson, Douglas B., Peng, Chengwei, Sosman, Jeffrey A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2015
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4346215/
https://ncbi.nlm.nih.gov/pubmed/25755682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014567469
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!